Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
ILM peeling
ITC in PAC
OSD
 
 
Survey

Do you use ocriplasmin to treat VMT in your practice?

Yes
9%
No
91%

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.


April 3, 2014
Retina surgery
ILM peeling may modify RNFL thickness
Internal limiting membrane (ILM) peeling surgery causes significant modification of retinal nerve fibre layer (RNFL) thickness, according to researchers at the Ophthalmology Units of the University of Bologna and the Sant’Orsola-Malpighi Polyclinic. More...
Clinical research
Peripheral iris thickness associated with ITC in PAC
Peripheral iris thickness is associated with iridotrabecular contact (ITC) in those who have angle closure, according to new research out of Japan. More...
Disease management
Scleral lenses help manage OSD
Commercially available scleral lenses can help manage moderate to severe ocular surface disease (OSD), according to new research out of the Mayo Clinic. As a bonus, the lenses can improve visual acuity (VA) in those whose vision has been negatively affected by the disease. More...
Product Profile
ZEISS Cataract Suite markerless
Align toric IOLs and skip the manual marking and data transfer steps with products designed to work together for markerless toric IOL alignment.
Read more
Event Profile
120th Congress of the French Society of Ophthalmology
Dates: 10–13 May 2014
Venue: Palais des Congrès, Porte Maillot, Paris
The SFO’s annual congress will bring together more than 8000 attendees, 100 exhibitors, 60 scientific sessions, 300 oral communications, 60 workshops, symposia with foreign Societies, 450 e-posters and e-films … Hot Topics will be discussed, a live surgery session on Monday 12th will be programmed, and a specific space (2nd floor) will be dedicated to technology and communication.
Read more:
Ranibizumab leading the anti-VEGF evolution
Considerations and new perspectives in anti-VEGF therapy. Read more:
Choosing and using the AcrySof IQ ReSTOR IOL family
Customize
d options for individual patients. Read more:
The Safety of anti-VEGF Therapy
Under the microscope, in trials and in clinical practice. Read more: